Editor's Note

Insys Therapeutics has reinvented itself and investors are taking note.


New positions are only added on Wednesday and Saturday except in special circumstances.


SD - Sandridge Energy - Company Description

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. Company description from FinViz.com.

Insys went through a couple years of trials when prior management did things that were not legal regarding opioid drugs. They paid doctors to subscribe them by asking them to speak at conferences for large speaking fees. They were caught and everybody paid the price.

Since then two-thirds of the board of directors are new and all are independent except for the CEO. The vast majority of management across the entire organization, including sales and marketing, are new to the company. More than 40% of the 330 employees are new and nearly 50% of the company's field force is new. They have reinvented Insys.

They have multiple drugs in their pipeline including naloxone, a nose spray for opiod overdose and epinephrine nasal spray for anaphylaxis. Both show promising results with a NDA expected on naloxone in 2018 and 2019 for epinephrine.

The company's prospects are improving and shares are rebounding from a three-year slide. Now that it is safe to invest in Insys again, portfolio managers are coming back.

Earnings August 7th.

I am going to reach way out to November on the option just in case we do see a nice rebound.

Buy INSY shares, currently $8.20, stop loss $7.25.
Optional: Buy Nov $9 call, currently $1.15, no stop loss.
(only 15 cents more than $10 call.)


No New Bearish Plays